Healthcare solutions company Evolent Health (NYSE: EVH) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales up 46.9% year on year to $652.5 million. The company’s full-year revenue guidance of $2.65 billion at the midpoint came in 5.9% above analysts’ estimates. Its non-GAAP profit of $0.02 per share was significantly above analysts’ consensus estimates.
Is now the time to buy EVH? Find out in our full research report (it’s free for active Edge members).
Evolent Health (EVH) Q2 CY2026 Highlights:
- Revenue: $652.5 million vs analyst estimates of $596.7 million (46.9% year-on-year growth, 9.4% beat)
- Adjusted EPS: $0.02 vs analyst estimates of -$0.02 (significant beat)
- Adjusted EBITDA: $28.05 million vs analyst estimates of $23.14 million (4.3% margin, 21.2% beat)
- The company lifted its revenue guidance for the full year to $2.65 billion at the midpoint from $2.5 billion, a 6% increase
- EBITDA guidance for the full year is $127.5 million at the midpoint, in line with analyst expectations
- Operating Margin: -1.5%, down from -0.3% in the same quarter last year
- Sales Volumes were down 1.8% year on year
- Market Capitalization: $403.8 million
StockStory’s Take
Evolent Health’s second quarter results drew a significant positive market reaction, reflecting outperformance versus Wall Street’s expectations on both revenue and profitability. Management pointed to the successful launch of the Highmark contract and robust customer renewals as key drivers. CEO Seth Blackley specifically highlighted that clinical engagement metrics for new partnerships, such as Aetna and Highmark, were trending above target, signaling strong execution in the company’s core value-based care solutions. Evolent’s ongoing focus on automation, particularly through its Auth Intelligence platform, was also cited as a contributor to operational efficiency.
Looking ahead, management’s guidance is grounded in anticipated expansion of its Performance Suite, particularly in oncology, and accelerated deployment of its AI-enabled authorization platform. Blackley emphasized, “We believe Q2 is a tipping point in our AI journey as we saw these efforts take root and accelerate past the pilot phases and to a point of meaningful scale.” The company is also preparing for new contract launches and expects cost-saving initiatives and improved operating leverage to offset ongoing headwinds in Medicaid and exchange membership. Management maintains confidence in delivering strong adjusted EBITDA growth in the coming year, despite industry-wide membership pressures.
Key Insights from Management’s Remarks
Management attributed the quarter’s performance to strong execution on new contract launches, customer renewals, and increased automation through its AI platform.
-
Performance Suite expansion: The launch of Highmark as a new Performance Suite client in May drove a significant increase in revenue and membership, with early indicators suggesting clinical and provider engagement rates exceeded initial targets.
-
Customer renewal strength: Evolent renewed three of its largest clients in 2026, including major partnerships with Aetna and Highmark, providing greater visibility and stability to its 2027 outlook and reinforcing its retention capabilities.
-
AI automation scaling: The Auth Intelligence platform, which automates prior authorization processes, achieved a milestone in Q2 by moving beyond pilot stage to meaningful operational scale. Management reported that one-third of previously manual authorizations are now automated, reducing approval timelines from days to minutes without sacrificing clinical quality.
-
Cross-sell momentum: A regional Blue Cross plan expanded its contract to adopt additional specialty products, illustrating successful cross-selling of Evolent’s technology and services to existing clients. Management believes such deals support margin improvement even when total contract value is modest.
-
Margin dynamics: The company experienced a decline in operating margin, driven by the mix shift toward Performance Suite contracts, which inherently operate at lower average margins but expand as contracts mature. Management expects margin recovery as newer contracts like Highmark and Aetna reach full operational maturity.
Drivers of Future Performance
Evolent’s forward guidance is shaped by continued Performance Suite expansion, broad AI automation, and ongoing cost discipline, offset by industry headwinds in Medicaid and exchange markets.
-
Performance Suite growth: Management expects the majority of near-term revenue growth to come from new and expanding Performance Suite contracts, particularly in oncology, with several large launches scheduled and a pipeline that now includes national and regional health plans.
-
AI-driven cost efficiency: The company plans to aggressively deploy its Auth Intelligence platform, targeting 80% of authorizations for automation, which is expected to improve operating margins and reduce administrative burden for providers and staff. Management believes these investments will support adjusted EBITDA growth even as membership headwinds persist.
-
Membership headwinds: Evolent anticipates continued pressure on Medicaid and exchange membership due to policy changes and client market exits. Management estimates a 20% decline among Medicaid expansion members, with offsetting growth from Medicare Advantage and new contract wins, but acknowledges that technology and operational improvements are necessary to maintain profitability.
Catalysts in Upcoming Quarters
Looking forward, the StockStory team is closely monitoring (1) the pace and quality of major Performance Suite launches, especially in oncology and with new large clients; (2) the operational impact and financial returns from scaling the Auth Intelligence platform across client contracts; and (3) the company’s ability to mitigate membership attrition in Medicaid and exchanges through cross-selling and new client wins. Progress on cost reduction and further customer renewals will also be critical markers for sustained growth.
Evolent Health currently trades at $3.62, up from $3.08 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).
High Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+271% between June 2020 and June 2025). Find your next big winner with StockStory today.
